You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀降中生製藥(01177.HK)目標價至8元 評級「買入」
瑞銀發表報告,降中生製藥(01177.HK)目標價由11.6元下調至8元,以反映公司的最新指引指銷售增長將放緩,以及來自合資公司利潤減少和研究費用增加,但仍看好其廣泛的產品管線和研發能力,予評級「買入」。 瑞銀指出,中生製藥去年收入和經調整純利分別增長13.6%和26.6%,腫瘤科、腦心血管科和呼吸科保持穩健的增長勢頭。由於對創新藥物和生物製劑的研發資源不斷增加,創新產品的收入貢獻升至64億元人民幣,佔總銷售額24%。 報告提到,中生製藥目前股價相當於預測2023年市盈率11倍,相比起同行的20倍平均水平,認為其估值被低估。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account